DE69637096D1 - Stabile n-propargyl-1-aminoindan enthaltende zusammensetzungen - Google Patents

Stabile n-propargyl-1-aminoindan enthaltende zusammensetzungen

Info

Publication number
DE69637096D1
DE69637096D1 DE69637096T DE69637096T DE69637096D1 DE 69637096 D1 DE69637096 D1 DE 69637096D1 DE 69637096 T DE69637096 T DE 69637096T DE 69637096 T DE69637096 T DE 69637096T DE 69637096 D1 DE69637096 D1 DE 69637096D1
Authority
DE
Germany
Prior art keywords
pct
aminoindan
propargyl
stable
containing compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69637096T
Other languages
English (en)
Other versions
DE69637096T2 (de
Inventor
Peskin Tirtsah Berger
Fanny Caciularu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11068003&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69637096(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of DE69637096D1 publication Critical patent/DE69637096D1/de
Application granted granted Critical
Publication of DE69637096T2 publication Critical patent/DE69637096T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE69637096T 1995-09-20 1996-09-18 Stabile n-propargyl-1-aminoindan enthaltende zusammensetzungen Expired - Lifetime DE69637096T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL11535795 1995-09-20
IL11535795A IL115357A (en) 1995-09-20 1995-09-20 Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
PCT/IL1996/000115 WO1997012583A2 (en) 1995-09-20 1996-09-18 Stable compositions containing n-propargyl-1-aminoindan

Publications (2)

Publication Number Publication Date
DE69637096D1 true DE69637096D1 (de) 2007-07-05
DE69637096T2 DE69637096T2 (de) 2008-01-31

Family

ID=11068003

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69637096T Expired - Lifetime DE69637096T2 (de) 1995-09-20 1996-09-18 Stabile n-propargyl-1-aminoindan enthaltende zusammensetzungen

Country Status (13)

Country Link
US (1) US6126968A (de)
EP (1) EP0858328B1 (de)
JP (1) JP4108750B2 (de)
AT (1) ATE362755T1 (de)
AU (1) AU728524B2 (de)
CA (1) CA2232310C (de)
DE (1) DE69637096T2 (de)
DK (1) DK0858328T3 (de)
ES (1) ES2287940T3 (de)
HU (1) HU225859B1 (de)
IL (1) IL115357A (de)
PT (1) PT858328E (de)
WO (1) WO1997012583A2 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
DE60029131T2 (de) 1999-10-27 2007-01-18 Teva Pharmaceutical Industries Ltd. Verwendung von 1-aminoindanderivaten zur behandlung der manie in verbindung mit manisch-depressiver erkrankung
PT1567152E (pt) 2002-11-15 2013-10-03 Teva Pharma Uso de rasagilina com riluzol para tratar a esclerose lateral amiotrófica
GB2411355B (en) 2004-02-27 2006-02-22 Niche Generics Ltd Pharmaceutical composition
CA2574925A1 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical dosage forms including rasagiline
US8367105B2 (en) 2004-11-10 2013-02-05 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
CA2587295A1 (en) * 2004-11-10 2006-05-18 Teva Pharmaceutical Industries Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
ATE521343T1 (de) * 2004-11-24 2011-09-15 Teva Pharma Im mund zerfallende zusammensetzungen von rasagilin
US20100167983A1 (en) * 2007-10-22 2010-07-01 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
DK1848415T3 (da) * 2005-02-17 2013-07-08 Teva Pharma Kombinationsterapi med glatirameracetat og rasagilin til behandling af multipel sklerose
US7815942B2 (en) 2005-02-23 2010-10-19 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
CA2630037C (en) 2005-11-17 2015-03-31 Teva Pharmaceutical Industries Ltd. Methods for isolating propargylated aminoindans
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
BRPI0620659A2 (pt) 2005-12-09 2017-10-31 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd método para a prevenção do aparecimento de sintomas de uma doença neurodegenerativa em um indivíduo predisposto à doença neurodegenerativa, método de redução de stress oxidante no cérebro de um indivíduo afligido com stress oxidante, método de tratamento de um indivíduo afligido com a degeneração cognitiva suave e composição farmacêutica
JP5701485B2 (ja) 2006-02-21 2015-04-15 テバ ファーマシューティカル インダストリーズ リミティド 多系統萎縮症の治療のためのラサギリンの使用
TW200744576A (en) 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
NZ571591A (en) 2006-04-03 2011-09-30 Teva Pharma Use of rasagiline for the treatment of restless legs syndrome
DE202006020710U1 (de) 2006-05-09 2009-12-31 Teva Pharmaceutical Industries Ltd. Zusammensetzungen mit Rosiglitazonmaleat
EP1892233A1 (de) * 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
ES2375761T3 (es) * 2006-12-14 2012-03-06 Teva Pharmaceutical Industries Ltd. Base de rasagilina cristalina sólida.
UA97382C2 (ru) 2006-12-14 2012-02-10 Тева Фармасьютікл Індастріз, Лтд. Таннат разагилина
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
AU2008296908B2 (en) * 2007-09-05 2014-01-09 Teva Pharmaceutical Industries, Ltd. Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
EA201070842A1 (ru) * 2008-01-11 2011-04-29 Тева Фармасьютикал Индастриз, Лтд. Препаративные формы разагилина, их получение и применение
US20090247537A1 (en) * 2008-03-25 2009-10-01 William Dale Overfield Methods for preventing or treating bruxism using dopaminergic agents
US20110117200A1 (en) * 2008-03-31 2011-05-19 Actavis Group Ptc Ehf Rasagiline mesylate particles and process for the preparation thereof
CA2727022A1 (en) * 2008-06-13 2009-12-17 Teva Pharmaceutical Industries Ltd. Rasagiline for parkinson's disease modification
US8334409B2 (en) * 2008-06-19 2012-12-18 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
CA2727017A1 (en) 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Process for preparing and drying solid rasagiline base
EP2218444A3 (de) 2009-01-23 2010-08-25 Teva Pharmaceutical Industries, Ltd. Rasagilinformulierung mit verzögerter Freisetzung
US20100189788A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline base formulation
EP2403485A2 (de) 2009-03-05 2012-01-11 Sandoz AG Pharmazeutische zusammensetzung mit rasagilinmesylat
DK2451771T3 (da) 2009-07-09 2014-09-08 Ratiopharm Gmbh Salte af rasagilin og farmaceutiske fremstillingsmåder heraf
CN102048717B (zh) † 2009-10-29 2014-02-19 重庆医药工业研究院有限责任公司 一种稳定的雷沙吉兰组合物
WO2011087791A1 (en) 2009-12-22 2011-07-21 Teva Pharmaceutical Industries Ltd. 3-keto-n-propargyl-1-aminoindan
MY153762A (en) 2010-04-30 2015-03-13 Teikoku Pharma Usa Inc Propynylaminoindan transdermal compositions
EP2389927A1 (de) 2010-05-30 2011-11-30 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Pharmazeutische Formulationen von Rasagilin
EP2598136A4 (de) 2010-07-27 2015-03-25 Teva Pharma Dispersionen von rasagilincitrat
AU2011282720B2 (en) 2010-07-27 2016-12-22 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
JP5906302B2 (ja) 2011-03-24 2016-04-20 テイコク ファーマ ユーエスエー インコーポレーテッド 作用剤層および作用剤変換層を含む経皮組成物
BR112014008555A2 (pt) * 2011-10-10 2017-04-18 Teva Pharma r(+)-n-formil-propargil-aminoindano
MX2014004201A (es) 2011-10-10 2015-01-12 Teva Pharma R(+)-n-metil-propargil-aminoindano.
JP2014534195A (ja) * 2011-10-10 2014-12-18 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンシトルアミド
JP5913614B2 (ja) 2011-11-09 2016-04-27 テイコク ファーマ ユーエスエー インコーポレーテッド 皮膚新生物の処置方法
DE102012000786A1 (de) 2012-01-18 2013-07-18 Stada Arzneimittel Ag Verfahren zur Herstellung einer festen pharmazeutischen Zusammensetzung, enthaltend den Wirkstoff Rasagilin
WO2013139387A1 (en) 2012-03-21 2013-09-26 Synthon Bv Stabilized pharmaceutical compositions comprising rasagiline salts
WO2013175493A1 (en) 2012-04-09 2013-11-28 Cadila Healthcare Limited Stable oral pharmaceutical compositions
WO2014028868A1 (en) 2012-08-17 2014-02-20 Teva Pharmaceutical Industries Ltd. Parenteral formulation of rasagiline
CA2887705C (en) 2012-11-02 2018-07-24 Teikoku Pharma Usa, Inc. Propynylaminoindan transdermal compositions
EP2764862A1 (de) * 2013-02-06 2014-08-13 Galenicum Health S.L. Tabletten mit unmittelbarer Freisetzung von Rasagilin Hemitartrate
ES2524865T1 (es) * 2013-02-06 2014-12-15 Galenicum Health S.L. Composiciones farmacéuticas estables en forma de comprimidos de liberación inmediata
CN115400090A (zh) * 2022-10-09 2022-11-29 北京新领先医药科技发展有限公司 一种雷沙吉兰的口崩片组合物及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1187017A (en) * 1966-07-16 1970-04-08 Aspro Nicholas Ltd Substituted 1-Amino Indanes and Tetrahydronaphthalens
GB8909793D0 (en) * 1989-04-28 1989-06-14 Beecham Group Plc Pharmaceutical formulation
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
CA2039742A1 (en) * 1990-04-23 1991-10-24 Andrew B. Dennis Tablet composition and method for problem pharmaceutical materials
IL112819A (en) * 1991-10-16 2001-11-25 Teva Pharma Fluorinated 1-aminoindan compounds and a process for their preparation
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
IL112779A (en) * 1994-03-01 1999-11-30 Gergely Gerhard Granular product or tablet containing an efferescent system and an active pharmaceutical substance and its preparation
GEP20012374B (en) * 1995-03-02 2001-03-25 Scherer Ltd R P Pharmaceutical Compositions Comprising Monoamine Oxidase B Inhibitors, Method for Obtaining the Same and Use

Also Published As

Publication number Publication date
ATE362755T1 (de) 2007-06-15
IL115357A (en) 2000-01-31
EP0858328A4 (de) 2001-07-11
DK0858328T3 (da) 2007-09-03
EP0858328B1 (de) 2007-05-23
IL115357A0 (en) 1995-12-31
CA2232310A1 (en) 1997-04-10
EP0858328A2 (de) 1998-08-19
HUP9802999A2 (hu) 1999-04-28
PT858328E (pt) 2007-08-20
CA2232310C (en) 2008-01-08
JP4108750B2 (ja) 2008-06-25
WO1997012583A2 (en) 1997-04-10
HUP9802999A3 (en) 1999-05-28
US6126968A (en) 2000-10-03
ES2287940T3 (es) 2007-12-16
AU6942796A (en) 1997-04-28
AU728524B2 (en) 2001-01-11
JPH11512736A (ja) 1999-11-02
HU225859B1 (en) 2007-11-28
WO1997012583A3 (en) 1997-06-05
DE69637096T2 (de) 2008-01-31

Similar Documents

Publication Publication Date Title
DE69637096D1 (de) Stabile n-propargyl-1-aminoindan enthaltende zusammensetzungen
UA26455C2 (uk) Лікарський препарат у формі таблеток із сповільhеhим вивільhеhhям активhого іhгредієhта
YU13695A (sh) Upotreba 2-fenil-3-aroilbenzotiofena i njihove farmaceutske formulacije
TR27835A (tr) Sübstitüe edilmis azadiokzasikloalkenler.
AU4264396A (en) Cosmetic or pharmaceutical compositions containing mangiferin or derivatives thereof
PT881901E (pt) Novas associacoes de principios activos contendo clopidogrel e um agente anti-trombotico
HK1010722A1 (en) Benzoyl guanidines, their production and their use in medicaments
CA2214026A1 (en) Pharmaceutical compositions comprising monoamine oxidase b inhibitors
FI972434A (fi) Lamotrigiiniä sisältävä farmaseuttinen koostumus
CA2203310A1 (fr) Comprime matriciel permettant la liberation prolongee du sel de sodium de tianeptine apres administration par voie orale
TR200000153T2 (tr) İl-5 inhibite eden 6-azaurasil türevleri.
DE69433012D1 (de) Verfahren zur herstellung von oralen dosierungsformulierungen enthaltend diclofenac
CA2152998A1 (en) Anti-hyperglycemia pharmaceutical composition
ES2078175A1 (es) Formulacion farmaceutica conteniendo clobetasona y tobramicina y sus aplicaciones.
AU2774292A (en) Toiletries composition
AU7470098A (en) Antithrombotic agents
MX9304403A (es) Derivados farmacologicamente activos de ó-(aminometilo terciario)-bencenmetanol
ZA965749B (en) Use of allylamines.
SI0805817T1 (de)
AU7274198A (en) Antithrombotic agents
MX9605633A (es) Composicion farmaceutica, metodo y dispositivo para prevenir o tratar resequedad de los ojos o enfermedad ocasionada por la misma.
TW333453B (en) Pharmaceutical composition comprising toremifene for use in the treatment of autoimmune diseases

Legal Events

Date Code Title Description
8364 No opposition during term of opposition